Previous close | 25.22 |
Open | 25.22 |
Bid | 38.80 |
Ask | 40.60 |
Strike | 130.00 |
Expiry date | 2024-04-19 |
Day's range | 25.22 - 25.22 |
Contract range | N/A |
Volume | |
Open interest | 5 |
In this article, we discuss the 25 richest billionaires in healthcare industry. To skip the detailed analysis of the healthcare industry, go directly to the 5 Richest Billionaires in Healthcare Industry. Global Healthcare Industry Outlook and Trends The global healthcare industry is going through a massive transition amid technological advancements, changing patient needs, and demographic […]
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United States, with addit